Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2024
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2024
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Image-guided percutaneous laser ablation for primary and secondary liver tumoursStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: 16 May 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Selective internal radiation therapy (SIRT) for neuroendocrine tumours metastatic to the liverStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 16 May 2024
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 3 July 2024
Transarterial Chemoembolisation for inoperable hepatocellular carcinomaStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC